@article {8863,
	title = {LC/MS Based Characterization Workflow of GLP-1 Therapeutic Peptide Liraglutide and Its Impurities [Agilent Technologies - C-CAMP Collaboration]},
	year = {2024},
	abstract = {<p>This application note demonstrates the power of the Agilent 1290 Infinity II liquid chromatograph (LC) coupled with the Agilent 6545XT AdvanceBio liquid chromatography/quadrupole time-of-flight mass spectrometer (LC/Q-TOF MS) for identification and characterization of therapeutic peptides. This application is exemplified for the GLP-1 agonist liraglutide and its impurities. The therapeutic peptide workflow within Agilent MassHunter BioConfirm software allows for accurate mass-based identification, sequence conformation, and identification of impurities, with extra or missing amino acid impurities that can arise during solid phase synthesis. These impurities may pose a potential safety risk and eventually may impact the efficacy of the product.</p>
},
	url = {https://www.agilent.com/cs/library/applications/an-liraglutide-impurities-characterization-5994-7727en-agilent.pdf},
	author = {Shadab Ahmad and Nirpendra Singh and Ashish Pargaonkar and Dheeraj Vig and Mike Knierman}
}
